CMS-HCC risk adjustment assigns a baseline coefficient (weight) to each qualifying HCC condition, but certain combinations of conditions can increase predicted cost beyond what would be expected by simply adding the two individual weights. These added increments are captured through disease interaction factors , which apply when specific conditions coexist (for example, diabetes with certain severe complications, or other paired conditions defined by the model). In outpatient CDI, this is why documentation must clearly support both diagnoses—each must be clinically evaluated/managed and meet reporting rules—because accurately capturing the interacting conditions can legitimately increase the beneficiary’s risk score. By contrast, hierarchies are designed to prevent double-counting within related condition families (the more severe manifestation typically supersedes a less severe one), which often limits—not adds—separate weights. Resource-based relative values and conversion factors belong to physician fee schedule payment methodology for services/procedures (RVUs and payment conversion), not HCC risk score calculation. Therefore, disease interactions are the correct concept that adds risk score weight beyond individual HCC coefficients.

For RAF impact in the CMS-HCC model, the most valuable provider education targets are conditions that (1) map to HCCs or interact with HCC hierarchies, and (2) are clearly within the specialist’s scope to assess and manage during visits. In this scenario, the endocrinologist is actively treating diabetes and its complications. Diabetes with peripheral neuropathy/vascular disease plus an active non-healing foot ulcer reflects significant diabetic disease burden and often supports additional required coding (e.g., diabetes complication code plus a separate site/severity ulcer code). The history of toe amputations is also important because amputation status can represent ongoing complexity, affects care planning (risk of recurrent ulcer/infection), and may contribute to risk capture depending on the model and associated complications. By contrast, CAD/COPD/HF may not be evaluated by the endocrinologist at the visit, “A1C” is a lab value (not a diagnosis), and “history of prostate cancer” generally does not risk-adjust like active malignancy. Therefore, educating on documenting diabetes, amputation status, and ulcer details best supports RAF accuracy.